The inhibition of PYGL and G6PD did not substantially affect the cell viability of KU812 ImaR cells more, but it decreased the cell viability of both KU812 P and ImaR cells which open new avenues to be considered in drug repurposing for CML. The gene discussed is PYGL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.